Last reviewed · How we verify
NCT06634966
Segmentectomy for Solid-dominant Lung Cancer
Phase 3 trial testing Segmentectomy in Segmentectomy in 277 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 277 |
| Start date | 1 July 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Segmentectomy
Conditions studied
- Segmentectomy — all drugs for Segmentectomy →
- Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →
Sponsor
Fudan University
Who can join
Adults 18 to 80, any sex, with Segmentectomy or Lung Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1025. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for solid-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: * The 5-year disease-free survival of patients having solid-dominant invasive lung cancer with size of 2-3cm; * The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06634966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Segmentectomy
Trials testing the same drug.
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06496659 — Segmentectomy After Induction Therapy (SAINT) · NA · recruiting
- NCT05717803 — Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) · Phase 3 · recruiting
- NCT04944563 — Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field · NA · recruiting
- NCT05695404 — Contribution of 3D Printing in Anatomical Lung Segmentectomies. · completed
Other recruiting trials for Segmentectomy
Currently open trials in the same condition.
- NCT06516198 — Auricular Acupressure in Prehabilitation · NA · recruiting
- NCT06496659 — Segmentectomy After Induction Therapy (SAINT) · NA · recruiting
- NCT05525923 — Personalized Postoperative Pain Management Following Thoracic Surgery in Adults · recruiting
- NCT05717803 — Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) · Phase 3 · recruiting
- NCT05453721 — Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Metho · NA · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06634966 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 10 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06634966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing